Kandy Therapeutics Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Aug 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 26, 2027The maintenance fee for Method of Treatment of Symptoms of Menopause (US 11,767,328) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Method of Treating Certain Sex Hormone-Dependent Diseases Administering a Soft Gelatin Capsule Comprising NK1 and NK3 Receptors Antagonists (US 11,787,820) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
Recent changes
- 3 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,093,242 | Crystalline Forms of a Pyridine Derivative In force · High confidence | In force | High confidence | |
| US 8,796,269 | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,195,205 | Uses of Dual NK1/NK3 Receptor Antagonists for Treating Sex-Hormone Diseases In force · High confidence | In force | High confidence | |
| US 10,774,091 | Soft Gelatin Capsule Formulation In force · High confidence | In force | High confidence | |
| US 11,767,328 | Method of Treatment of Symptoms of Menopause In force · Low confidence | In force | Low confidence | |
| US 11,787,820 | Method of Treating Certain Sex Hormone-Dependent Diseases Administering a Soft Gelatin Capsule Comprising NK1 and NK3 Receptors Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 12,264,164 | Method of Treatment of Symptoms of Menopause In force · Low confidence | In force | Low confidence | |
| US 11,591,346 | Method of Treatment of Symptoms of Menopause In force · High confidence | In force | High confidence | |
| US 12,473,260 | New Chemical Process for Making 6-Chloro-4-(4-Fluoro-2-Methylphenyl)PYRIDIN-3-Amine a Key Intermediate of NT-814 In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned